Thromboprophylaxis in pregnancy: Difference between revisions
From IDWiki
Content deleted Content added
Imported from text file |
(No difference)
|
Latest revision as of 01:17, 4 July 2020
Indications for prophylaxis
| Patient | FHx of VTE? | Prophylaxis |
|---|---|---|
| Prior VTE with provoked, transient risk factor | — | None |
| Prior VTE either unprovoked or estrogen-related | — | Antepartum and postpartum |
| Homozygous Factor V Leiden | Yes | Antepartum and postpartum |
| Homozygous prothrombin gene mutation | Yes | Antipartum and postpartum |
| Antithrombin-III deficiency | Yes | Antepartum and postpartum |
| Other thrombophilia | Yes | Postpartum only |
| Homozygous Factor V Leiden | No | Postpartum only |
| Homozygous prothrombin gene mutation | No | Postpartum only |
| Other thrombophilia | No | None |
| Antithrombin-III deficiency | No | None |
Prophylaxis regimens
| Timing | Management |
|---|---|
| Antepartum | Prophylactic or intermediate-dose LMWH |
| Postpartum | Prophylactic or intermediate-dose LMWH, or warfarin (INR 2-3), for 6 weeks |